UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries

Danish medical journal, 2015-04, Vol.62 (4), p.B5054

Halladin, Natalie Løvland

2015

Link zum Volltext

Verfügbarkeit prüfen

Melatonin for pre- and postoperative anxiety in adults

Cochrane database of systematic reviews, 2015-04, Vol.2015 (4), p.CD009861-CD009861

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of intracoronary melatonin on ischemia–reperfusion injury in ST-elevation myocardial infarction

Heart and vessels, 2016-01, Vol.31 (1), p.88-95

2016

Link zum Volltext

Verfügbarkeit prüfen

An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions

Danish medical journal, 2017-01, Vol.64 (1)

2017

Link zum Volltext

Verfügbarkeit prüfen

Intracoronary and systemic melatonin to patients with acute myocardial infarction: protocol for the IMPACT trial

Danish medical journal, 2014-02, Vol.61 (2), p.A4773

2014

Link zum Volltext

Verfügbarkeit prüfen

Melatonin does not affect oxidative/inflammatory biomarkers in a closed-chest porcine model of acute myocardial infarction

In vivo (Athens), 2014-07, Vol.28 (4), p.483-488

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Diabetes care, 2018-05, Vol.41 (5), p.1009-1016

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Diabetes, obesity & metabolism, 2017-06, Vol.19 (6), p.858-865

2017

Link zum Volltext

Verfügbarkeit prüfen

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1399-1408

2019

Link zum Volltext

Verfügbarkeit prüfen

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

The lancet. Diabetes & endocrinology, 2019-08, Vol.7 (8), p.596-605

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES

Endocrine practice, 2019-02, Vol.25 (2), p.144-155

2019

Link zum Volltext

Verfügbarkeit prüfen

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100units/mL at 26weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

Diabetes, obesity & metabolism, 2020-05, Vol.22 (5), p.873-878

2020

Link zum Volltext

Verfügbarkeit prüfen

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

Diabetes, obesity & metabolism, 2020-05, Vol.22 (5), p.873-878

2020

Link zum Volltext

Verfügbarkeit prüfen

Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

147-OR: DUAL VIII: Significantly Longer Time to Treatment Intensification with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) in a 104-Week (Wk) Randomized Trial Mirroring Clinical Practice

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

Journal of diabetes science and technology, 2021-05, Vol.15 (3), p.636-645

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial

Journal of cardiovascular translational research, 2017-12, Vol.10 (5-6), p.470-479

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S58

2017

Link zum Volltext

Verfügbarkeit prüfen

148 - Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S58-S58

2017

Link zum Volltext

Verfügbarkeit prüfen

138 - Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S47-S47

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S47

2018

Link zum Volltext

Verfügbarkeit prüfen

Closed-chest porcine model is superior in intervention studies of ischaemia reperfusion injury

Ugeskrift for læger, 2012-06, Vol.174 (26), p.1807

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(24)

Sprache

Englisch
(23)
Dänisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(10)
Female
(9)
Aged
(8)
Endocrinology & Metabolism
(7)
Male
(7)
Middle Aged
(7)
Blood Glucose
(6)
Diabetes Mellitus, Type 2 - Drug Therapy
(6)
Hypoglycemia
(6)
Insulin
(6)
Adult
(5)
Antidiabetics
(5)
Diabetes
(5)
Diabetes Mellitus
(5)
Drug Combinations
(5)
Animals
(4)
Clinical Trials
(4)
Disease Models, Animal
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries

Melatonin for pre- and postoperative anxiety in adults

Effects of intracoronary melatonin on ischemia–reperfusion injury in ST-elevation myocardial infarction

An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions

Intracoronary and systemic melatonin to patients with acute myocardial infarction: protocol for the IMPACT trial

Melatonin does not affect oxidative/inflammatory biomarkers in a closed-chest porcine model of acute myocardial infarction

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100units/mL at 26weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

147-OR: DUAL VIII: Significantly Longer Time to Treatment Intensification with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) in a 104-Week (Wk) Randomized Trial Mirroring Clinical Practice

Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

148 - Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

138 - Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics

Closed-chest porcine model is superior in intervention studies of ischaemia reperfusion injury

Suchergebnisse filtern